Sunday, February 8, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

CSI Compressco Fiscal Year 2024 Capital Expenditure and EBITDA Forecast

Elaine Mendonca by Elaine Mendonca
March 1, 2024
in Breaking News
0
Oil and Gas Producers Stock Market Today
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

As of March 1, 2024, CSI Compressco is forecasting capital expenditures for the fiscal year to fall within the range of $52.0 million to $69.0 million. Alongside this, they are projecting an adjusted EBITDA between $135 million and $145 million for the same period.

These estimates indicate the company’s investment plans and financial performance expectations for the upcoming fiscal year.

CSI Compressco LP (CCLP) Stock Analysis and Performance Update – March 1, 2024

On March 1, 2024, CSI Compressco LP (CCLP) had a relatively positive day in the stock market. The stock closed at $1.99, which was a $0.02 increase from the previous trading day, marking a 1.02% rise. Additionally, in after-hours trading, the stock continued to climb, gaining an additional $0.09.

Looking at the overall performance of CCLP, the stock is currently trading in the middle of its 52-week range and is above its 200-day simple moving average. This indicates that the stock has been relatively stable and is showing signs of strength in its price momentum.

Investors may find this information encouraging, as it suggests that CCLP has the potential for further growth in the future. The positive price movement on March 1, 2024, coupled with the stock trading above its 200-day moving average, could indicate that the stock is in an uptrend.

It is important for investors to continue monitoring the performance of CCLP and stay informed about any news or developments that could impact the stock’s price. By staying informed and conducting thorough research, investors can make well-informed decisions about whether to buy, sell, or hold onto their CCLP shares.

CCLP Stock Shows Promising Growth in Financial Metrics on March 1, 2024

On March 1, 2024, CCLP stock showed promising performances as the company reported positive growth in its financial metrics. According to data from CNN Money, CCLP’s total revenue for the past year was $353.40 million, showing a 16.18% increase compared to the previous year. In the third quarter of the same year, the company’s total revenue stood at $99.71 million, marking a 3.03% increase since the last quarter.

CCLP’s net income for the past year was reported at -$22.16 million, which may seem like a loss at first glance. However, it is worth noting that this figure represents a significant improvement of 54.85% compared to the previous year. In the third quarter of 2024, the company’s net income was -$943.00 thousand, showing a remarkable 63.18% increase since the last quarter.

Earnings per share (EPS) is another important metric to consider when evaluating a company’s performance. In the past year, CCLP reported an EPS of -$0.16, which represents an 80.46% increase compared to the previous year. In the third quarter of 2024, the company’s EPS was -$0.01, showing a 63.33% increase since the last quarter.

Overall, CCLP’s stock performances on March 1, 2024, reflect positive growth in key financial metrics such as total revenue, net income, and EPS. Investors may view these improvements as a sign of the company’s resilience and potential for future growth.

Tags: CCLP
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
GD stock news

Goldman Sachs Reinstates ColgatePalmolive with Buy Rating and 93 Price Target

Financings on laptop

Unveiling the Latest Trends in Broad-Spectrum Commodity Pricing Intelligence

Finance_Assets (3)

Utz Brands Analyst Scoreboard Recent Ratings and Price Targets

Recommended

Camping World Stock

Can Camping World Maintain Its Dividend Amid Market Pressures?

5 months ago
Trinity Biotech Stock

Trinity Biotech Faces Critical Nasdaq Compliance Deadline

5 months ago
DVY stock news

Amarin Strengthens Position and Maximizes Shareholder Value Through Share Repurchase Agreement with Cantor Fitzgerald

2 years ago
ASTeMobile Stock

ASTeMobile Shares Face Mounting Pressure as Investor Confidence Wanes

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

Repay Holdings: Annual Report to Test Strategic Refinancing Success

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Trending

Cassava Sciences Stock
Analysis

Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays

by Jackson Burston
February 8, 2026
0

The future of Cassava Sciences appears uncertain following the definitive termination of its Alzheimer's disease program. Detailed...

DroneShield Stock

DroneShield Shares Face Headwinds Despite Record Performance

February 8, 2026
Rock Tech Lithium Stock

Rock Tech Lithium: Investors Await the Final Go-Ahead

February 8, 2026
Puma Biotechnology Stock

Puma Biotechnology Sets Date for Full-Year Financial Disclosure

February 8, 2026
Quanterix Stock

Quanterix Seeks FDA Clearance for Groundbreaking Alzheimer’s Blood Test

February 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Cassava Sciences Confirms Alzheimer Drug Failure and Faces Regulatory Delays
  • DroneShield Shares Face Headwinds Despite Record Performance
  • Rock Tech Lithium: Investors Await the Final Go-Ahead

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com